NO chimeras as therapeutic agents in Alzheimer's disease

Current Alzheimer Research

Volumn 3, Issue 3, 2006, Pages 237-245

  Thatcher, Gregory R J ^a   Bennett, Brian M ^b   Reynolds, James N ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Alzheimer's; BDNF; cGMP; Cognition; Dementia; Neurodegeneration; Nitrate; Nitric oxide

Indexed keywords

AMYLOID; AMYLOID PRECURSOR PROTEIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLOMETHIAZOLE; CYCLIC GMP; FLURBIPROFEN; GLYCERYL TRINITRATE; GT 061; GT 1061; GT 715; GUANYLATE CYCLASE; ISOSORBIDE DINITRATE; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINIC RECEPTOR; NITRIC ACID DERIVATIVE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; SCOPOLAMINE; SIGNAL PEPTIDE; THIAZOLE DERIVATIVE;

ALZHEIMER DISEASE; ANGINA PECTORIS; BIOCHEMISTRY; CELL SURVIVAL; CEREBROVASCULAR ACCIDENT; CHOLINERGIC SYSTEM; CLINICAL TRIAL; CONVULSION; DEMENTIA; DOWN REGULATION; DRUG ACTIVITY; ENZYME ACTIVATION; EVIDENCE BASED MEDICINE; HUMAN; HYPOTENSION; LEARNING; MEMORY; NERVE CELL; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SYNAPSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BIOMIMETIC MATERIALS; HUMANS; NITRATES; NITRIC OXIDE; RECEPTORS, NICOTINIC;

EID: 33745625064     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720506777632925     Document Type: Review

References (180)

1. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, et al., Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 61: 59-66 (2004).
2. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al., Current concepts in mild cognitive impairment. Arch Neurol 58: 1985-1992 (2001).
3. Steinberg M, Munro CA, Samus Q, P VR, Brandt J, and Lyketsos CG.. Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study. Int J Geriatr Psychiatry 19 : 144-150 (2004).
4. Schweitzer I, Tuckwell V, O'Brien J, and Ames D. Is late onset depression a prodrome to dementia? Int J Geriatr Psychiatry 17: 997-1005 (2002).
5. Copeland MP, Daly E, Hines V, Mastromauro C, Zaitchik D, Gunther J, and Albert M. Psychiatric symptomatology and prodromal Alzheimer's disease. Alzheimer Dis Assoc Disord 17: 1-8 (2003).
6. Mesulam M. The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? Learn Mem 11: 43-49 (2004).
7. Sirvio J. Strategies that support declining cholinergic neurotransmission in Alzheimer's disease patients. Gerontology 45 Suppl 1: 3-14 (1999).
8. Bartus RT, Dean RL, 3rd Beer B, and Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 217: 408-414 (1982).
9. Francis PT, Palmer AM, Snape M, and Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 66: 137-147 (1999).
10. Benzi G, and Moretti A. Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? Eur J Pharmacol 346 : 1-13 (1998).
11. Schneider LS. AD2000: donepezil in Alzheimer's disease. Lancet 363: 2100-2101 (2004).
12. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, and Bentham P. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 363: 2105-2115 (2004).
13. Hardy JA, and Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185 (1992).
14. Lorenzo A, and Yankner BA. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. USA 91: 12243-12247 (1994).
15. Zerbinatti CV, Wozniak DF, Cirrito J, Cam JA, Osaka H, Bales KR, Zhuo M, Paul SM, Holtzman DM and Bu G. Increased soluble amyloid-{beta} peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. Proc Natl Acad Sci U S A (2004).
16. Van Dam D, D'Hooge R, Staufenbiel M, Van Ginneken C, Van Meir F and De Deyn PP. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci 17: 388-396 (2003).
17. Richardson JC, Kendal CE, Anderson R, Priest F, Gower E, Soden P, Gray R, Topps S, Howlett DR, Lavender D, Clarke NJ, Barnes JC, Haworth R, Stewart MG and Rupniak HT. Ultrastructural and behavioural changes precede amyloid deposition in a transgenic model of Alzheimer's disease. Neuroscience 122: 213-228 (2003).
18. Diez M, Koistinaho J, Kahn K, Games D and Hokfelt T. Neuropeptides in hippocampus and cortex in transgenic mice overexpressing V717F beta-amyloid precursor protein - initial observations. Neuroscience 100: 259-286 (2000).
19. Wang Z, Chang L, Klein WL, Thatcher GRJ and Venton DL. Per-6-substituted-per-6-deoxy beta-cyclodextrins Inhibit the Formation of beta-Amyloid Peptide Derived Soluble Oligomers. J Med Chem 47: 3329-3333 (2004).
20. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA and Klein WL. Alzheimer's disease-affected brain: Presence of oligomeric Ab ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Nat Acad Sc USA 100: 10417-10422 (2003).
21. Wu J, Anwyl R and Rowan MJ. beta-Amyloid-(1-40) increases long-term potentiation in rat hippocampus in vitro. Eur. J. Pharmacol. 284: R1-3 (1995).
22. Kowalska MA and Badellino K. beta-Amyloid protein induces platelet aggregation and supports platelet adhesion. Biochem. Biophys. Res. Commun. 205: 1829-1835 (1994).
23. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D and Seubert P. Immunization with amyloid-b attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature (London) 400: 173-177 (1999).
24. Mattson MP, Guo ZH and Geiger JD. Secreted form of amyloid precursor protein enhances basal glucose and glutamate transport and protects against oxidative impairment of glucose and glutamate transport in synaptosomes by a cyclic GMP- mediated mechanism. J Neurochem 73: 532-537 (1999).
25. Kemp PM, Holmes C, Hoffmann S, Wilkinson S, Zivanovic M, Thom J, Bolt L, Fleming J and Wilkinson DG. A randomised placebo controlled study to assess the effects of cholinergic treatment on muscarinic receptors in Alzheimer's disease. J Neurol Neurosurg Psychiatry 74: 1567-1570 (2003).
26. Rosler M. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract Suppl, 20-36 (2002).
27. Van Dam D and De Deyn PP. Cognitive evaluation of disease-modifying efficacy of Galantamine and Memantine in the APP23 model. Eur Neuropsychopharmacol 16: 69-59 (2006).
28. Lin L, Georgievska B, Mattsson A and Isacson O. Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation. Proc Natl Acad Sci U S A 96: 12108-12113 (1999).
29. Isacson O and Lin L. Cholinergic modulation of amyloid processing and dementia in animal models of Alzheimer's disease. Ann N Y Acad Sci 920: 309-314 (2000).
30. Capsoni S, Ugolini G, Comparini A, Ruberti F, Berardi N and Cattaneo A. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc Natl Acad Sci U S A 97: 6826-6831 (2000).
31. Winblad B, Wimo A and Almkvist O. Outcome measures in Alzheimer's disease: do they go far enough? Dement Geriatr Cogn Disord 11 Suppl 1: 3-10 (2000).
32. Jani J, Prettyman R, Aslam M, Trantor J and Cherryman G. A retrospective study of neuroradiological abnormalities detected on structural magnetic resonance imaging of the brain in elderly patients with cognitive impairment. Int J Geriatr Psychiatry 15: 1054-1060 (2000).
33. Mattson MP, Lovell MA, Furukawa K and Markesbery WR. Neurotrophic factors attenuate glutamate-induced accumulation of peroxides, elevation of intracellular Ca2+ concentration, and neurotoxicity and increase antioxidant enzyme activities in hippocampal neurons. J Neurochem 65: 1740-1751 (1995).
34. Fischer W, Gage FH and Bjorklund A. Degenerative Changes in Forebrain Cholinergic Nuclei Correlate with Cognitive Impairments in Aged Rats. Eur J Neurosci 1: 34-45 (1989).
35. Korsching S, Auburger G, Heumann R, Scott J and Thoenen H. Levels of nerve growth factor and its mRNA in the central nervous system of the rat correlate with cholinergic innervation. Embo J 4: 1389-1393 (1985).
36. Whittemore SR, Ebendal T, Larkfors L, Olson L, Seiger A, Stromberg I and Persson H. Development and regional expression of beta nerve growth factor messenger RNA and protein in the rat central nervous system. Proc Natl Acad Sci U S A 83: 817-821 (1986).
37. Isacson O, Seo H, Lin L, Albeck D and Granholm AC. Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh. Trends Neurosci 25: 79-84 (2002).
38. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP and Reitz AB. beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 275: 5626-5632 (2000).
39. Albeck DS, Backman C, Veng L, Friden P, Rose GM and Granholm A. Acute application of NGF increases the firing rate of aged rat basal forebrain neurons. Eur J Neurosci 11: 2291-2304 (1999).
40. Balkowiec A and Katz DM. Activity-dependent release of endogenous brain-derived neurotrophic factor from primary sensory neurons detected by ELISA in situ. J Neurosci 20: 7417-7423 (2000).
41. Blochl A and Thoenen H. haracterization of nerve growth factor (NGF) release from hippocampal neurons: evidence for a constitutive and an unconventional sodium-dependent regulated pathway. Eur J Neurosci 7: 1220-1228 (1995).
42. Granholm AC, Sanders LA and Crnic LS. Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Exp Neurol 161: 647-663 (2000).
43. Jaffar S, Counts SE, Ma SY, Dadko E, Gordon MN, Morgan D and Mufson EJ. Neuropathology of mice carrying mutant APP(swe) and/or PS1(M146L) transgenes: alterations in the p75(NTR) cholinergic basal forebrain septohippocampal pathway. Exp Neurol 170: 227-243 (2001).
44. Lin L, LeBlanc CJ, Deacon TW and Isacson O. Chronic cognitive deficits and amyloid precursor protein elevation after selective immunotoxin lesions of the basal forebrain cholinergic system. Neuroreport 9: 547-552 (1998).
45. Crutcher KA, Scott SA, Liang S, Everson WV and Weingartner J. Detection of NGF-like activity in human brain tissue: increased levels in Alzheimer's disease. J Neurosci 13: 2540-2550 (1993).
46. Wang C, Wurtman RJ and Lee RK. myloid precursor protein and membrane phospholipids in primary cortical neurons increase with development, or after exposure to nerve growth factor or Abeta(1-40). Brain Res 865: 157-167 (2000).
47. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399: A23-31 (1999).
48. Wallace WC, Akar CA and Lyons WE. Amyloid precursor protein potentiates the neurotrophic activity of NGF. Brain Res Mol Brain Res 52: 201-212 (1997).
49. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH and Sweatt JD. eta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 21: 4125-4133 (2001).
50. Tong L, Thornton PL, Balazs R and Cotman CW. Beta -amyloid-(1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival Is not compromised. J Biol Chem 276: 17301-17306 (2001).
51. Yamamoto-Sasaki M, Ozawa H, Saito T, Rosler M, and Riederer P. Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type. Brain Res 824: 300-303 (1999).
52. Gibb BJ and Garthwaite J. Subunits of the nitric oxide receptor, soluble guanylyl cyclase, expressed in rat brain. Eur J Neurosci 13: 539-544 (2001).
53. Cary SP, Winger JA and Marletta MA. Tonic and acute nitric oxide signaling through soluble guanylate cyclase is mediated by non-heme nitric oxide, ATP, and GTP. Proc Natl Acad Sci USA 102: 13064-13069 (2005).
54. Mitchell DA, Erwin PA, Michel T and Marletta MA. S-Nitrosation and regulation of inducible nitric oxide synthase. Biochemistry 44 : 4636-4647 (2005).
55. Winger JA and Marletta MA. Expression and characterization of the catalytic domains of soluble guanylate cyclase: interaction with the heme domain. Biochemistry 44: 4083-4090(2005).
56. Bredt DS and Snyder SH. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci USA 86: 9030-9033 (1989).
57. Garthwaite J, Garthwaite G, Palmer RM and Moncada S.NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol 172: 413-416 (1989).
58. Hanley MR and Iversen LL. Muscarinic cholinergic receptors in rat corpus striatum and regulation of guanosine cyclic 3′,5′-monophosphate. Mol Pharmacol 14: 246-255 (1978).
59. Wang X and Robinson PJ. Cyclic GMP-dependent protein kinase and cellular signaling in the nervous system. J Neurochem 68: 443-456 (1997).
60. Dawson TM, Dawson VL and Snyder SH. A novel neuronal messenger molecule in brain: the free radical, Nitric oxide. Ann Neurol 32: 297-311 (1992).
61. Son H, Lu YF, Zhuo M, Arancio O, Kandel ER and Hawkins RD. The specific role of cGMP in hippocampal LTP. Learn Mem 5: 231-245 (1998).
62. Lu YF, Kandel ER and Hawkins RD. itric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J Neurosci 19: 10250-10261(1999).
63. Law A, Gauthier S and Quirion R. Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's type. Brain Res Brain Res Rev 35: 73-96(2001).
64. Lee JM, Zipfel GJ and Choi DW. The changing landscape of ischaemic brain injury mechanisms. Nature 399: A7-14(1999).
65. Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen HS, Sucher NJ, Loscalzo J, Singel DJ and Stamler JS. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds [see comments]. Nature 364: 626-632(1993).
66. Nowicki JP, Duval D, Poignet H and Scatton B. Nitric oxide mediates neuronal death after focal cerebral ischemia in the mouse. Eur J Pharmacol 204: 339-340(1991).
67. Hantraye P, Brouillet E, Ferrante R, Palfi S, Dolan R, Matthews RT and Beal MF. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med 2: 1017-1021(1996).
68. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM and Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 5: 1403-1409(1999).
69. Kohno K, Ohta S, Kohno K, Kumon Y, Mitani A, Sakaki S and Kataoka K. Nitric oxide synthase inhibitor reduces delayed neuronal death in gerbil hippocampal CA1 neurons after transient global ischemia without reduction of brain temperature or extracellular glutamate concentration. Brain Res 738 : 275-280 (1996).
70. Barger SW, Fiscus RR, Ruth P, Hofmann F and Mattson MP. Role of cyclic GMP in the regulation of neuronal calcium and survival by secreted forms of beta-amyloid precursor. J Neurochem 64: 2087-2096(1995).
71. Farinelli SE, Park DS and Greene LA. Nitric oxide delays the death of trophic factor-deprived PC12 cells and sympathetic neurons by a cGMP-mediated mechanism. J Neurosci 16: 2325-2334(1996).
72. Estevez AG, Spear N, Thompson JA, Cornwell TL, Radi R, Barbeito L and Beckman JS. Nitric oxide-dependent production of cGMP supports the survival of rat embryonic motor neurons cultured with brain-derived neurotrophic factor. J Neurosci 18: 3708-3714(1998).
73. Ju TC, Chen SD, Liu CC and Yang DI. Protective effects of S-nitrosoglutathione against amyloid beta-peptide neurotoxicity. Free Radic Biol Med 38: 938-949 (2005).
74. Wirtz-Brugger F and Giovanni A. Guanosine 3′,5′-cyclic monophosphate mediated inhibition of cell death induced by nerve growth factor withdrawal and beta-amyloid: protective effects of propentofylline. Neuroscience 99: 737-750 (2000).
75. Chiueh CC. Neuroprotective properties of nitric oxide. Ann N Y Acad Sci 890 : 301-311(1999).
76. Tenneti L, D'Emilia DM and Lipton SA. Suppression of neuronal apoptosis by S-nitrosylation of caspases. Neurosci. Lett. 236 :139-142(1997).
77. Lipton SA. Role of nitric oxide in neuronal protection versus apoptosis. Nitric Oxide, 453-464(2000).
78. Troy CM, Rabacchi SA, Friedman WJ, Frappier TF, Brown K and Shelanski ML. Caspase-2 mediates neuronal cell death induced by beta-amyloid. J Neurosci 20 :1386-1392 (2000).
79. Garthwaite G and Garthwaite J. Cyclic GMP and cell death in rat cerebellar slices. Neuroscience 26: 321-326 (1988).
80. Paris D, Town T, Parker T, Humphrey J and Mullan M. beta-Amyloid vasoactivity and proinflammation in microglia can be blocked by cGMP-elevating agents. Ann N Y Acad Sci 903: 446-450(2000).
81. Liu B and Hong JS. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 304 : 1-7(2003).
82. Paris D, Town T and Mullan M. Novel strategies for opposing murine microglial activation. Neurosci Lett 278:5-8 (2000).
83. Andoh T, Chock PB and Chiueh CC. Preconditioning-mediated neuroprotection: role of nitric oxide, cGMP, and new protein expression. Ann N Y Acad Sci 962 :1-7 (2002).
84. Andoh T, Chiueh CC and Chock PB. Cyclic GMP-dependent protein kinase regulates the expression of thioredoxin and thioredoxin peroxidase-1 during hormesis in response to oxidative stress-induced apoptosis. J Biol Chem 278 : 885-890 (2003).
85. Gonzalez-Zulueta M, Feldman AB, Klesse LJ, Kalb RG, Dillman JF, Parada LF, Dawson TM and Dawson VL. Requirement for nitric oxide activation of p21(ras)/extracellular regulated kinase in neuronal ischemic preconditioning. Proc Natl Acad Sci USA 97:436-441(2000).
86. Chalimoniuk M and Strosznajder JB. Aging modulates nitric oxide synthesis and cGMP levels in hippocampus and cerebellum. Effects of amyloid beta peptide. Mol Chem Neuropathol 35: 77-95(1998).
87. Zhuo M, Kandel ER and Hawkins RD. Nitric oxide and cGMP can produce either synaptic depression or potentiation depending on the frequency of presynaptic stimulation in the hippocampus. Neuroreport 5 :1033-1036 (1994).
88. Schweighofer N and Ferriol G. Diffusion of nitric oxide can facilitate cerebellar learning: A simulation study. Proc Natl Acad Sci USA 97 :10661-10665 (2000).
89. Arancio O, Kandel ER and Hawkins RD. Activity-dependent long-term enhancement of transmitter release by presynaptic 3′,5′-cyclic GMP in cultured hippocampal neurons. Nature 376 :74-80 (1995).
90. Lewin MR and Walters ET. Cyclic GMP pathway is critical for inducing long-term sensitization of nociceptive sensory neurons. Nat Neurosci 2 :18-23 (1999).
91. Barcellos CK, Bradley PM, Burns BD and Webb AC. Effects of nitric oxide release in an area of the chick forebrain which is essential for early learning. Brain Res Dev Brain Res 121: 79-87(2000).
92. Bernabeu R, Schmitz P, Faillace MP, Izquierdo I and Medina JH. Hippocampal cGMP and cAMP are differentially involved in memory processing of inhibitory avoidance learning. Neuroreport 7:585-588 (1996).
93. Bernabeu R, Schroder N, Quevedo J, Cammarota M, Izquierdo I and Medina JH. Further evidence for the involvement of a hippocampal cGMP/cGMP-dependent protein kinase cascade in memory consolidation. Neuroreport 8 :2221-2224 (1997).
94. Prickaerts J, Steinbusch HW, Smits JF and de Vente J. Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: effects of 7-nitroindazole and zaprinast. Eur J Pharmacol 337:125-136 (1997).
95. Prickaerts J, de Vente J, Honig W, Steinbusch HW and Blokland A. cGMP, but not cAMP, in rat hippocampus is involved in early stages of object memory consolidation. Eur J Pharmacol 436: 83-87(2002).
96. Boulton CL, Southam E and Garthwaite J. Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase. Neuroscience 69:699-703(1995).
97. Zhuo M, Hu Y, Schultz C, Kandel ER and Hawkins RD. Role of guanylyl cyclase and cGMP-dependent protein kinase in long-term potentiation. Nature 368 :635-639(1994).
98. Bon CL and Garthwaite J. On the role of nitric oxide in hippocampal long-term potentiation. J Neurosci 23: 1941-1948(2003).
99. Jerusalinsky D, Kornisiuk E and Izquierdo I. Cholinergic neurotransmission and synaptic plasticity concerning memory processing. Neurochem Res 22: 507-515 (1997).
100. Krause M and Pedarzani P. A protein phosphatase is involved in the cholinergic suppression of the Ca(2+)-activated K(+) current sI(AHP) in hippocampal pyramidal neurons. Neuropharmacology 39: 1274-1283(2000).
101. Chien WL, Liang KC, Teng CM, Kuo SC, Lee FY and Fu WM. Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzylindazole. Mol Pharmacol 63: 1322-1328 (2003).
102. Lu YF and Hawkins RD. Ryanodine receptors contribute to cGMP-induced late-phase LTP and CREB phosphorylation in the hippocampus. J Neurophysiol 88,:1270-1278(2002).
103. Hawkins RD, Son H and Arancio O. Nitric oxide as a retrograde messenger during long-term potentiation in hippocampus. Prog Brain Res 118:155-172(1998).
104. Hawkins RD. NO honey, I don't remember. Neuron 16 :465-467(1996).
105. Klann E Roberson ED Knapp LT and Sweatt JD. role for superoxide in protein kinase C activation and induction of long-term potentiation. J Biol Chem 273:4516-4522(1998).
106. Carlstrom L, Ke ZJ, Unnerstall JR, Cohen RS and Pandey SC. Estrogen modulation of the cyclic AMP response element-binding protein pathway. Effects of long-term and acute treatments. Neuroendocrinology 74:227-243(2001).
107. Einat H, Yuan P, Gould TD, Li J, Du J, Zhang L, Manji HK and Chen G..The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci 23 : 7311-7316(2003).
108. Morozov A, Muzzio IA, Bourtchouladze R, Van-Strien N, Lapidus K, Yin D, Winder DG, Adams JP, Sweatt JD and Kandel ER. Rap1 couples cAMP signaling to a distinct pool of p42/44MAPK regulating excitability, synaptic plasticity, learning, and memory. Neuron 39: 309-325(2003).
109. Adams JP and Sweatt JD. Molecular psychology: roles for the ERK MAP kinase cascade in memory. Annu Rev Pharmacol Toxicol 42 :135-163(2002).
110. Anderson AE, Adams JP, Qian Y, Cook RG, Pfaffinger PJ and Sweatt JD. v4.2 phosphorylation by cyclic AMP-dependent protein kinase. J Biol Chem 275: 5337-5346(2000).
111. Thiels E, Kanterewicz BI, Norman ED, Trzaskos JM and Klann E. Long-term depression in the adult hippocampus in vivo involves activation of extracellular signal-regulated kinase and phosphorylation of Elk-1. J Neurosci 22:2054-2062(2002).
112. Dineley KT, Weeber EJ, Atkins C, Adams JP, Anderson AE and Sweatt JD. Leitmotifs in the biochemistry of LTP induction: amplification, integration and coordination. J Neurochem 77: 961-971(2001).
113. Sulser F. The role of CREB and other transcription factors in the pharmacotherapy and etiology of depression. Ann Med 34: 348-356(2002).
114. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ and Monteggia LM. Neurobiology of depression. Neuron 34: 13-25 (2002).
115. Nakagawa S, Kim JE, Lee R, Chen J, Fujioka T, Malberg J, Tsuji S and Duman RS. Localization of phosphorylated cAMP response element-binding protein in immature neurons of adult hippocampus. J Neurosci 22:9868-9876(2002).
116. D'Sa C and Duman RS. Antidepressants and neuroplasticity. Bipolar Disord 4: 183-194(2002).
117. Vaidya VA and Duman RS. Depresssion - emerging insights from neurobiology. Br Med Bull 57: 61-79(2001).
118. Wu GY, Deisseroth K and Tsien RW. Activity-dependent CREB phosphorylation: convergence of a fast, sensitive calmodulin kinase pathway and a slow, less sensitive mitogen-activated protein kinase pathway. Proc Natl Acad Sci USA 98: 2808-2813(2001).
119. Kasahara J, Fukunaga K and Miyamoto E. Activation of calcium/calmodulin- dependent protein kinase IV in long term potentiation in the rat hippocampal CA1 region. J Biol Chem 276 :24044-24050(2001).
120. Glazner GW and Mattson MP. Differential effects of BDNF, ADNF9, and TNFalpha on levels of NMDA receptor subunits, calcium homeostasis, and neuronal vulnerability to excitotoxicity. Exp Neurol 161:442-452(2000).
121. Cheng A, Wang S, Yang D, Xiao R and Mattson MP. Calmodulin mediates brain-derived neurotrophic factor cell survival signaling upstream of Akt kinase in embryonic neocortical neurons. J Biol Chem 278:7591-7599 (2003).
122. Cheng A, Wang S, Cai J, Rao MS and Mattson MP. itric oxide acts in a positive feedback loop with BDNF to regulate neural progenitor cell proliferation and differentiation in the mammalian brain. Dev Biol 258 :319-333(2003).
123. Allsopp TE, Kiselev S, Wyatt S and Davies AM. Role of Bcl-2 in the brain-derived neurotrophic factor survival response. Eur J Neurosci 7:1266-1272 (1995).
124. Chung YH, Kim EJ, Shin CM, Joo KM, Kim MJ, Woo HW, et al. Age-related changes in CREB binding protein immunoreactivity in the cerebral cortex and hippocampus of rats. Brain Res 956 :312-318(2002).
125. Baquet ZC, Gorski JA and Jones KR. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci 24: 4250-4258(2004).
126. Yurek DM and Fletcher-Turner A. esion-induced increase of BDNF is greater in the striatum of young versus old rat brain. Exp Neurol 161: 392-396(2000).
127. Ernfors P and Bramham CR. The coupling of a trkB tyrosine residue to LTP. Trends Neurosci 26:171-173(2003).
128. Ying SW, Futter M, Rosenblum K, Webber MJ, Hunt SP, Bliss TV, et al. Brain-derived neurotrophic factor induces long-term potentiation in intact adult hippocampus: requirement for ERK activation coupled to CREB and upregulation of Arc synthesis. J Neurosci 22: 1532-1540(2002).
129. Gooney M and Lynch MA. Long-term potentiation in the dentate gyrus of the rat hippocampus is accompanied by brain-derived neurotrophic factor-induced activation of TrkB. J Neurochem 77:1198-1207(2001).
130. Vanhoutte P and Bading H. Opposing roles of synaptic and extrasynaptic NMDA receptors in neuronal calcium signalling and BDNF gene regulation. Curr Opin Neurobiol 13: 366-371(2003).
131. Buhot MC, Martin S and Segu L. Role of serotonin in memory impairment. Ann Med 32:210-221(2000).
132. Lai MK, Tsang SW, Francis PT, Keene J, Hope T, Esiri MM, et al. Postmortem serotoninergic correlates of cognitive decline in Alzheimer's disease. Neuroreport 13: 1175-1178(2002).
133. Stoo R and Poo MM. Synaptic modulation by neurotrophic factors. Prog Brain Res 109 :359-364(1996).
134. Garthwaite J and Boulton CL. Nitric oxide signaling in the central nervous system. Annu Rev Physiol 57 :683-706(1995).
135. Schuman EM and Madison DV. Nitric oxide and synaptic function. Annu Rev Neurosci 17: 153-183(1994).
136. Bredt DS and Snyder SH. (1994). Transient nitric oxide synthase neurons in embryonic cerebral cortical plate, sensory ganglia, and olfactory epithelium. Neuron 13 :301-313(1994).
137. Lo YY and Cruz TF. Involvement of reactive oxygen species in cytokine and growth factor induction of c-fos expression in chondrocytes. J Biol Chem 270 :11727-11730(1995).
138. Xiong H, Yamada K, Han D, Nabeshima T, Enikolopov G, Carnahan J, et al. Mutual regulation between the intercellular messengers nitric oxide and brain-derived neurotrophic factor in rodent neocortical neurons. Eur J Neurosci 11: 1567-1576(1999).
139. Shors TJ, Miesegaes G, Beylin A, Zhao M, Rydel T and Gould E. Neurogenesis in the adult is involved in the formation of trace memories. Nature 410 :372-376(2001).
140. Olivieri G, Otten U, Meier F, Baysang G, Dimitriades-Schmutz B, Muller-Spahn F, et al. Beta-amyloid modulates tyrosine kinase B receptor expression in SHSY5Y neuroblastoma cells: influence of the antioxidant melatonin. Neuroscience 120 :659-665(2003).
141. Tang Y, Yamada K, Kanou Y, Miyazaki T, Xiong X, Kambe F, et al. Patiotemporal expression of BDNF in the hippocampus induced by the continuous intracerebroventricular infusion of beta-amyloid in rats. Brain Res Mol Brain Res 80:188-197(2000).
142. Chiueh CC and Rauhala P. The redox pathway of S-nitrosoglutathione, glutathione and nitric oxide in cell to neuron communications. Free Radic Res 31 :641-650(1999).
143. Suo Z, Fang C, Crawford F and Mullan M. Superoxide free radical and intracellular calcium mediate A beta(1-42) induced endothelial toxicity. Brain Res 762 :144-152(1997).
144. Thomas T, Thomas G, McLendon C, Sutton T and Mullan M. beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380 :168-171(1996).
145. Suhara T, Magrane J, Rosen K, Christensen R, Kim HS, Zheng B, et al. Abeta42 generation is toxic to endothelial cells and inhibits eNOS function through an Akt/GSK-3beta signaling-dependent mechanism. Neurobiol Aging 24:437-451 (2003)..
146. Vitolo OV, Sant'Angelo A, Costanzo V, Battaglia F, Arancio O and Shelanski M. Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci USA 99 :13217-13221(2002).
147. Puzzo D, Vitolo O, Trinchese F, Jacob J.P, Palmeri A and Arancio O. Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP- responsive element-binding protein pathway during hippocampal synaptic plasticity. J Neurosci 25:6887-6897(2005).
148. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8 :1051-1058 (2005).
149. Russwurm M, Wittau N and Koesling D. Guanylyl cyclase/PSD-95 interaction: targeting of the nitric oxide- sensitive alpha2beta1 guanylyl cyclase to synaptic membranes. J Biol Chem 276 :44647-44652 (2001).
150. Mergia E, Russwurm M, Zoidl G and Koesling D. Major occurrence of the new alpha2beta1 isoform of NO-sensitive guanylyl cyclase in brain. Cell Signal 15 :189-195(2003).
151. Brenman JE and Bredt DS. ynaptic signaling by nitric oxide. Curr Opin Neurobiol 7: 374-378(1997).
152. Thatcher GRJ, Nicolescu AC, Bennett BM and Toader V. Nitrates and no release: contemporary aspects in biological and medicinal chemistry. Free Radic Biol Med 37:1122-1143(2004).
153. Thatcher GRJ, Bennett BM and Reynolds JN. Nitric oxide mimetic molecules as therapeutic agents in Alzheimer's disease. Curr Alzheimer Res 2 :171-182 (2005).
154. Keefer LK. Nitric oxide (NO)- and nitroxyl (HNO)-generating diazeniumdiolates (NONOates): emerging commercial opportunities. Curr Top Med Chem 5: 625-636(2005).
155. King SB. N-hydroxyurea and acyl nitroso compounds as nitroxyl (HNO) and nitric oxide (NO) donors. Curr Top Med Chem 5:665-673(2005).
156. Yoshida K and Kita Y. Hydroxyimine NO-donors; FK409 and derivatives. Curr Top Med Chem 5 :675-685(2005).
157. Cai TB, Lu D and Wang PG. N-hydroxyguanidines as substrates of nitric oxide synthases. Curr Top Med Chem 5:721-736(2005).
158. Bolla M, Almirante N and Benedini F. Therapeutic potential of nitrate esters of commonly used drugs. Curr Top Med Chem 5 :707-720(2005).
159. DiFabio J, Ji Y, Vasiliou V, Thatcher GR and Bennett BM. Role of mitochondrial aldehyde dehydrogenase in nitrate tolerance. Mol Pharmacol 64:1109-1116 (2003).
160. Shelton RJ, Velavan P, Nikitin NP, Coletta AP, Clark AL, Rigby AS, et al. Clinical trials update from the American Heart Association meeting: ACORN-CSD, primary care trial of chronic disease management, PEACE, CREATE, SHIELD, A-HeFT, GEMINI, vitamin E meta-analysis, ESCAPE, CARP, and SCD-HeFT cost-effectiveness study. Eur J Heart Fail 7:127-135 (2003).
161. Franciosa JA, Taylor AL, Cohn JN, Yancy CW, Ziesche S, Olukotun A, et al. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail 8 :128-135 (2002).
162. van Groen T and Kadish I. Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology. Brain Res Brain Res Rev 48 :370-378(2005).
163. Jantzen PT Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, et al. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 22:2246-2254 (2002).
164. Zavorin SI, Artz JD, Dumitrascu A, Nicolescu A, Scutaru D, Smith SV, et al. Nitrate esters as nitric oxide donors: SS-nitrates. Org Lett 3 :1113-1116 (2001).
165. Yang K, Artz JD, Lock J, Sanchez C, Bennett BM, Fraser AB, et al. Synthesis of novel organic nitrate esters: guanylate cyclase activation and tissue relaxation. J Chem Soc Perkin Trans 1 :1073-1075 (1996).
166. Reynolds JN, Bennett BM, Boegman RJ, Jhamandas K, Ratz JD, Zavorin SI, et al. Neuroprotection against ischemic brain injury conferred by a novel nitrate ester. Bioorg Med Chem Lett 12 :2863-2866 (2002).
167. Smith S, Dringenberg HC, Bennett BM, Thatcher GR and Reynolds JN. A novel nitrate ester reverses the cognitive impairment caused by scopolamine in the Morris water maze. Neuroreport 11 :3883-3886 (2000).
168. Thatcher GRJ, Bennett BM, Dringenberg HC and Reynolds JN. Novel nitrates as NO mimetics directed at Alzheimer's disease. J Alzheimers Dis 6 :S75-84 (2004).
169. Smith CP, Bores GM, Petko W, Li M, Selk DE, Rush DK, et al. Pharmacological activity and safety profile of P10358, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease. J. Pharmacol. Exp. Ther. 280 : 710-720 (1997).
170. Bennett BM, Reynolds JN, Prusky GT, Douglas RM, Sutherland RJ, Thatcher GRJ. Neuropsychopharmacology, in press (2006).
171. Toong S, Xiong ZG, Zavorin SI, Bai D, Orser BA, Thatcher GR, Reynolds JN and MacDonald JF. Modulation of AMPA receptors by a novel organic nitrate. Can J Physiol Pharmacol 79: 422-429 (2001).
172. Lindberg UH. Compounds related to clomethiazole. IV. 4-Methylthiazoles and oxazoles with polar side-chains and some other analogs of clomethiazole. Acta Pharmaceutica Suecica 8 : 39-48 (1971).
173. Lindberg UH. Hypnotic and anticonvulsant agents related to the thiazole part of thiamine. Acta Pharmaceutica Suecica 8 :647-660 (1971).
174. Green AR. Clomethiazole (Zendra) in acute ischemic stroke: basic pharmacology and biochemistry and clinical efficacy. Pharmacol Ther 80 :123-147 (1998).
175. Marshall JW, Cross AJ and Ridley RM. Functional benefit from clomethiazole treatment after focal cerebral ischemia in a nonhuman primate species. Exp Neurol 156 :121-129 (1999).
176. Farooque M, Isaksson J, Jackson DM and Olsson Y. Clomethiazole (ZENDRA, CMZ) improves hind limb motor function and reduces neuronal damage after severe spinal cord injury in rat. Acta Neuropathol (Berl) 98 :22-30 (1999).
177. Charonnat R, Lechat P and Chareton J. From a convulsive to an anticonvulsive product in the thiamine series. Therapie 11 :261-264 (1956).
178. Torres EM, Perry TA, Blockland A, Wilkinson LS, Wiley RG, Lappi DA and Dunnet SB. Behavioural, histochemical and biochemical consequences of selective immunolesions in discrete regions of the basal forebrain cholinergic system. Neuroscience 63 :95-122 (1994).
179. Stephan A and Phillips AG. A case for a non-transgenic animal model of Alzheimer's disease. Genes Brain Behav 4 :157-172 (2005).
180. Prusky GT, Douglas RM, Nelson L, Shabanpoor A and Sutherland RJ. Visual memory task for rats reveals an essential role for hippocampus and perirhinal cortex. Proc Natl Acad Sci USA 101 :5064-5068 (2004).